Reinnervate

Sedgefield, United Kingdom Founded: 2002 • Age: 24 yrs Acquired By ReproCELL
3D cell culture based on polystyrene based scaffold.
Annual revenue - Latest available
Total funding $2.0M 2 rounds
Employees - Tracked headcount
Investors 3 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About Reinnervate

Reinnervate is a company based in Sedgefield (United Kingdom) founded in 2002 was acquired by ReproCELL in August 2014. Reinnervate has raised $2 million across 2 funding rounds from investors including ReproCELL, Parkwalk and NorthStar Education Institute. Reinnervate operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.

  • Headquarter Sedgefield, United Kingdom
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $2 M (USD)

    in 2 rounds

  • Latest Funding Round
    Not available
  • Investors
    ReproCELL

    & 2 more

  • Employee Count
    Not available
  • Acquired by
    ReproCELL

    (Aug 05, 2014)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Reinnervate

Reinnervate has successfully raised a total of $2M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Reinnervate

Reinnervate has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ReproCELL, Parkwalk and NorthStar Education Institute.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Tech companies are invested in by Parkwalk venture capital firm.
Locked Locked Locked
-
Locked Locked Locked
Leading global supplier of iPS-derived cells, stem cell reagents, human biofluids, and 3D cell culture.
Locked Locked Locked
Premium access

Investor details for Reinnervate

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Reinnervate

Investments
Premium access

Investment portfolio details for Reinnervate

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Reinnervate

Premium access

Detailed financials for Reinnervate

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Reinnervate Comparisons

Reinnervate Primary company
Description
3D cell culture based on polystyrene based scaffold.
Location
Sedgefield, United Kingdom
Founded Year
2002
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Reinnervate

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Reinnervate

Reinnervate operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of pharmaceuticals and vaccines for various therapeutic areas
Locked Locked Locked
Antibody-siRNA complexes are developed for cancer treatment.
Locked Locked Locked
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
Locked Locked Locked
Yeast cells are genetically engineered to produce medicinal products.
Locked Locked Locked
Developing novel drugs based on a proteome-wide ligand and target discovery platform
Locked Locked Locked
CRISPR-engineered cell and gene therapies are developed for research applications.
Premium access

Detailed competitors of Reinnervate

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Reinnervate

Premium access

Complete news archive for Reinnervate

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Reinnervate

Reinnervate was founded in 2002 and raised its 1st funding round 8 years after it was founded.

Reinnervate is headquartered in Sedgefield, United Kingdom. It is registered at Sedgefield, County Durham, United Kingdom.

Reinnervate is a funded company, having raised a total of $2M across 2 funding rounds to date.

Reinnervate (a ReproCELL company), is a spin-out company from Durham University that offers the Alvetex 3D cell culture platform. The technology is based on the research performed by Prof. Stefan Przyborski who also serves as the companys CSO. Alvetex is a highly porous polystyrene scaffold that is engineered into a 200 micron thick membrane. The scaffold is presented in various ways including multi-welled plates and well inserts, for use with conventional culture plasticware and a novel medium perfusion system. Alvetex 3D cell culture enables scientist to grow tissue-like structures that better mimic in vivo biology than current 2D monolayer methods. The potential to improve the predictive nature of cell-based assays by combining 3D culture and iPSC-derived cell products is attracting a lot of interest in the drug development industry. Reinnervates products are currently used by researchers in over 300 universities and companies globally.

Reinnervate's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

Reinnervate has 3 investors. Key investors include ReproCELL, Parkwalk, and NorthStar Education Institute.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available